Reference sources: deteroutdoor.com, doctorpedia.com To arrange an appointment, please call HOTLINE or make your reservation directly HERE
Writingoriginal draft: JS
Giloteaux L, ONeal A, Castro-Marrero J, Levine SM, Hanson MR
In the retatrutide Phase 2 trial (Jastreboff et al., NEJM 2023), many participants found that symptoms such as diarrhoea, nausea, and abdominal discomfort improved after the initial weeks at a given dose, consistent with experience seen with licensed GLP-1 receptor agonists
However, individuals have claimed their gastroparesis side effects did not resolve after stopping the medication, and have resulted in other permanent gastrointestinal injuries